Global Obesity Treatment Market Overview:
Global Obesity Treatment Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2024-2035, Considering the Base Year As 2025.
Global Obesity Treatment Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2024-2035, with base year as 2025. This research study of Obesity Treatment involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Obesity Treatment Market:
The Obesity Treatment Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Obesity Treatment Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Obesity Treatment Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Obesity Treatment market has been segmented into:
Biliopancreatic diversion with Duodenal Switch (BPD/DS
By Application, Obesity Treatment market has been segmented into:
Appetite suppressants
Combination drugs
Malabsorption
and Satiety drugs
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Obesity Treatment market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Obesity Treatment market.
Top Key Players Covered in Obesity Treatment market are:
VIVUS
Inc. (U.S.)
Arena Pharmaceuticals
Inc. (U.S.)
Hoffmann-La Roche
Ltd.(Switzerland)
Novo Nordisk A/S (Denmark)
Orexigen Therapeutics
Inc. (U.S.)
Allergan (Republic of Ireland)
Cousin Biotech (France)
EnteroMedics
Inc. (U.S.)
Johnson & Johnson Services
Inc. (U.S.)
Medtronic (U.S.)
USGI Medical
Inc. (U.S.)
Mediflex Surgical Products (U.S.)
Covidien plc (Republic of Ireland)
Olympus Corporation (Japan)
Takeda Pharmaceuticals Company Limited
Eisai Co. Ltd.
Novo Nordisk A/S
Zafgen
Rhythm Pharmaceuticals
Zydus Cadila
Norgine B.V.
Vivus Therapeutics
Arena Pharmaceuticals Inc.
Orexigen Therapeutics Inc
among others
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Obesity Treatment Market Type
4.1 Obesity Treatment Market Snapshot and Growth Engine
4.2 Obesity Treatment Market Overview
4.3 Biliopancreatic diversion with Duodenal Switch (BPD/DS
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.3.3 Biliopancreatic diversion with Duodenal Switch (BPD/DS: Geographic Segmentation Analysis
Chapter 5: Obesity Treatment Market Application
5.1 Obesity Treatment Market Snapshot and Growth Engine
5.2 Obesity Treatment Market Overview
5.3 Appetite suppressants
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.3.3 Appetite suppressants: Geographic Segmentation Analysis
5.4 Combination drugs
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.4.3 Combination drugs: Geographic Segmentation Analysis
5.5 Malabsorption
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.5.3 Malabsorption: Geographic Segmentation Analysis
5.6 and Satiety drugs
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.6.3 and Satiety drugs: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Obesity Treatment Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 VIVUS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC. (U.S.)
6.4 ARENA PHARMACEUTICALS
6.5 INC. (U.S.)
6.6 HOFFMANN-LA ROCHE
6.7 LTD.(SWITZERLAND)
6.8 NOVO NORDISK A/S (DENMARK)
6.9 OREXIGEN THERAPEUTICS
6.10 INC. (U.S.)
6.11 ALLERGAN (REPUBLIC OF IRELAND)
6.12 COUSIN BIOTECH (FRANCE)
6.13 ENTEROMEDICS
6.14 INC. (U.S.)
6.15 JOHNSON & JOHNSON SERVICES
6.16 INC. (U.S.)
6.17 MEDTRONIC (U.S.)
6.18 USGI MEDICAL
6.19 INC. (U.S.)
6.20 MEDIFLEX SURGICAL PRODUCTS (U.S.)
6.21 COVIDIEN PLC (REPUBLIC OF IRELAND)
6.22 OLYMPUS CORPORATION (JAPAN)
6.23 TAKEDA PHARMACEUTICALS COMPANY LIMITED
6.24 EISAI CO. LTD.
6.25 NOVO NORDISK A/S
6.26 ZAFGEN
6.27 RHYTHM PHARMACEUTICALS
6.28 ZYDUS CADILA
6.29 NORGINE B.V.
6.30 VIVUS THERAPEUTICS
6.31 ARENA PHARMACEUTICALS INC.
6.32 OREXIGEN THERAPEUTICS INC
6.33 AMONG OTHERS
Chapter 7: Global Obesity Treatment Market By Region
7.1 Overview
7.2. North America Obesity Treatment Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Appetite suppressants
7.2.3.2 Combination drugs
7.2.3.3 Malabsorption
7.2.3.4 and Satiety drugs
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Obesity Treatment Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Appetite suppressants
7.3.3.2 Combination drugs
7.3.3.3 Malabsorption
7.3.3.4 and Satiety drugs
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Obesity Treatment Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Appetite suppressants
7.4.3.2 Combination drugs
7.4.3.3 Malabsorption
7.4.3.4 and Satiety drugs
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Obesity Treatment Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Appetite suppressants
7.5.3.2 Combination drugs
7.5.3.3 Malabsorption
7.5.3.4 and Satiety drugs
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Obesity Treatment Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Appetite suppressants
7.6.3.2 Combination drugs
7.6.3.3 Malabsorption
7.6.3.4 and Satiety drugs
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Obesity Treatment Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Biliopancreatic diversion with Duodenal Switch (BPD/DS
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Appetite suppressants
7.7.3.2 Combination drugs
7.7.3.3 Malabsorption
7.7.3.4 and Satiety drugs
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Obesity Treatment Scope:
|
Report Data
|
Obesity Treatment Market
|
|
Obesity Treatment Market Size in 2025
|
USD XX million
|
|
Obesity Treatment CAGR 2025 - 2032
|
XX%
|
|
Obesity Treatment Base Year
|
2024
|
|
Obesity Treatment Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
VIVUS, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), Hoffmann-La Roche, Ltd.(Switzerland), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc. (U.S.), Allergan (Republic of Ireland), Cousin Biotech (France), EnteroMedics, Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Mediflex Surgical Products (U.S.), Covidien plc (Republic of Ireland), Olympus Corporation (Japan), Takeda Pharmaceuticals Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen, Rhythm Pharmaceuticals, Zydus Cadila, Norgine B.V., Vivus Therapeutics, Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc, among others.
|
|
Key Segments
|
By Type
Biliopancreatic diversion with Duodenal Switch (BPD/DS
By Applications
Appetite suppressants
Combination drugs
Malabsorption
and Satiety drugs
|
